Device Trial Radar · NCT04579692
MR Guided Focused Ultrasound (FUS) for the Treatment of Trigeminal Neuralgia
Last checked: Nov 20, 2026Latest source record: Jul 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
10
Actual
Start
Aug 16, 2021
Primary completion
May 28, 2026
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- University of Maryland, BaltimoreAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Focused Ultrasound Foundation; InSightec
- First posted
- Oct 8, 2020
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Device feasibility
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 21 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the safety and effectiveness of MRI-guided focused ultrasound (MRgFUS) for treating Trigeminal Neuralgia. Trigeminal Neuralgia (pain) is a type of pain involving the face that can be disabling to those it affects.
Conditions
- Trigeminal Neuralgia
Interventions
ExAblate Transcranial treatmentDevice
Patients' head will be placed in ExAblate device to hold it still for the treatment. The ExAblate Transcranial helmet will be placed on their head. The investigators will measure the study participant's heart, blood pressure, temperature, and breathing rate before the treatment begins. MRI scans will be taken to make sure the ultrasound waves will be aimed exactly within the target. A series of MR images will be taken to identify the target area, and plan the study treatment. The study investigators will decide on the area of participant's brain that will be treated. The ExAblate Transcranial system will compute a plan to cover the treatment area. This area is gradually heated while monitoring the patient's responses and neurologic examination.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Treatment related adverse eventsTime frame: All events will be reported up to 6 months from treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
University of Maryland Medical Center
Baltimore, Maryland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.